HIV

Top news of the week from Specialty Pharmacy Times.

Raltegravir (Isentress) is an integrase inhibitor for use in combination with other antiretroviral agents for HIV-1 in newborn infants weighing at least 2 kg.

Millions of individuals gain access to HIV treatment, but there are significant gaps that need to be addressed to end the epidemic.

Americans are getting tested and diagnosed with HIV sooner after infection, according to a recently-published CDC Vital Signs report.

Closing gaps in testing at-risk populations could increase HIV diagnoses.

Increased virologic failure and drug resistance following dolutegravir monotherapy prompt researchers to recommend against its use in patients with HIV.

Top news of the week from Specialty Pharmacy Times.

Juluca can replace ART in patients with HIV.

Juluca is indicated as a complete therapy for patients with HIV-1.

Juluca is indicated as a complete therapy for patients with HIV-1.

Many immunotherapy clinical trials exclude HIV-positive patients with cancer.

HIV-positive patients need to maintain healthy body weight, quit smoking, eat well, exercise regularly and treat hypertension, diabetes and dyslipidemia.

Health care stakeholders need to do a better job of adjusting testing and treatment to follow the HIV epidemic.

Identification of the last unknown protein in HIV could lead to a cure for the virus.

Gut microbiome alterations have been associated with frailty in older individuals with HIV.

"Gut microbiome" is becoming a buzzword in the health care community.

Human genome sequence variations can have a significant impact on the efficacy of HIV antiviral therapy.

HIV-positive children administered antiretroviral therapy have changes in their white matter brain tissue.

Pharmacists can expect to see considerably more information about the implications of pharmacogenetics for drug treatment in every disease state.

Top news of the week from Specialty Pharmacy Times.

Once-daily HIV treatment found to be highly effective and well-tolerated in treating antiretroviral-naïve HIV-1 patients.

How pharmacists can reduce polypharmacy and potentially inappropriate prescribing among the aging HIV population.

With the aging of the HIV-positive population and the necessity of using multiple medications – many of which have significant potential for drug interactions – it's important to look for ways that we can minimize risk for this population.

A derivative of a natural compound could stop HIV replication and prevent a viral rebound.

Developing a vaccine that launches immune attacks against cancer proves to be difficult.